BCMA Recombinant Rabbit mAb (SDT-2397-10)
BCMA Recombinant Rabbit mAb (SDT-2397-10)
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | BCMA |
| Synonyms | Tumor necrosis factor receptor superfamily member 17; B-cell maturation protein; CD269; BCM; TNFRSF17 |
| Immunogen | Recombinant Protein |
| Location | Cell membrane |
| Accession | Q02223 |
| Clone Number | SDT-2397-10 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | Sandwich ELISA |
| Reactivity | Hu |
| Cross Reactivity | No cross-reactivity against human BAFF or CD19 protein |
| Purification | Protein A |
| Concentration | 2 mg/ml |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.03% Proclin 300 |
| Stability & Storage | 12 months from date of receipt, 2 to 8 °C as supplied |
Background
CD269, also known as B-cell maturation antigen (BCMA) or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a type III transmembrane receptor of the TNF-receptor superfamily encoded by the TNFRSF17 gene, expressed predominantly on mature B cells, plasmablasts, and plasma cells, where it binds ligands BAFF and APRIL to activate NF-κB and MAPK8/JNK pathways, thereby promoting B-cell survival, differentiation, and immunoglobulin production while playing a crucial role in autoimmune responses. Serum B-cell maturation antigen (sBCMA) is the cleaved form of B-cell maturation antigen (BCMA), found at low levels in the serum of normal patients and generally elevated in patients with multiple myeloma (MM). Changes in sBCMA levels have been found to correlate with a MM patient’s clinical status in response to treatment.
Picture
Picture
Paired Recommendations
